A Cohort Study Of The Effect Of Hemagglutinase On The Prognosis Of Adult Hypertensive Cerebral Hemorrhage

Background:Hemorrhagic stroke is the most serious type of stroke.It has the characteristics of fast onset,severe illness,and poor prognosis.The mortality rate in the acute phase is as high as 30%to 40%,and survivors often have residual sequelae..The causes of cerebral hemorrhage include hypertension,arteriovenous malformations,cerebral amyloid angiopathy,adverse drug reactions,coagulation dysfunction,etc.Among them,hypertension is the most common cause of disease,accounting for about 50%to 70%.In the treatment of cerebral hemorrhage,the main principles are blood pressure lowering,application of hemostatic drugs,reduction of intracranial pressure,life support treatment,prevention and treatment of complications,etc.In the application of hemostatic drugs,there is not enough quality literature to recommend what to use Which kind of medicine hemostatic treatment.The results of research on hemostatic drugs such as rF?a and tranexamic acid,which had been expected in the past,were also unsatisfactory.Recent studies have shown that rF ? a does not significantly reduce the risk of severe disability or death at 90 days after the onset of cerebral hemorrhage,but instead increases the incidence of arterial thromboembolic events.Tranexamic acid can reduce the volume of intracranial hematoma and early neurological deterioration in patients with cerebral hemorrhage,but it does not significantly improve the disability rate and long-term mortality after cerebral hemorrhage,and there is also a risk of causing vascular embolism.Therefore,in cases other than scientific research,for patients with hypertensive cerebral hemorrhage with normal coagulation function,rF?a and tranexamic acid hemostatic therapy are not recommended.In China,some doctors give patients with cerebral hemorrhage to use hemagglutinin preparations for hemostasis treatment,but there is no high-quality evidence that the hemostatic drug can improve the prognosis of patients with cerebral hemorrhage.Method and purpose:Using the method of retrospective cohort study,by collecting hospitalization data of patients with hypertensive cerebral hemorrhage who were admitted to Nanfang Hospital from January 1,2010 to July 1,2018,according to whether they were used within 24 hours For hemagglutinin,the patients were divided into a hemagglutinin hemostatic treatment group and a non-hemagglutinin hemostatic treatment group,and the main outcome indicators between the two groups were calculated to see whether there were significant differences.The purpose is to determine whether the use of hemagglutinin hemostasis can significantly reduce the length of hospitalization of patients with cerebral hemorrhage,improve the patient's nerve function,and reduce the degree of disability of the patient,etc.,and evaluate the safety of drugs used in patients with hypertensive cerebral hemorrhage.Results:160 cases were included in this study,including 95 cases in the non-thrombin hemostasis treatment group and 65 cases in the hemagglutinin hemostasis treatment group.Except for the time of onset,there were no statistically significant differences between the other baseline characteristic indicators.In terms of age,gender,location of bleeding,time from onset to admission,amount of bleeding,systolic blood pressure at admission,whether blood was flowing in After the concomitant factors such as subventricular zone,blood from the subcutaneous area,NIHSS score,GCS score,ICH score,etc.Binary logistic regression was used to analyze the incidence of adverse events during hospitalization and the incidence of adverse outcomes during discharge.The p value of the incidence of adverse events during hospitalization was 0.041(p<0.05).The difference was statistically significant.The p value of the incidence of adverse outcomes was 0.746(p>0.05),and the difference was not statistically significant.Multiple linear regression was performed on the length of hospitalization,p value was 0.897(p>0.05),the difference was not statistically significant.Conclusion:In patients with hypertensive intracerebral hemorrhage with normal coagulation function,the use of hemagglutinin treatment in the early stage(within 24 hours)did not improve the neurological prognosis and disability at the time of discharge,nor did it reduce the length of hospitalization,but increased the number of patients.The incidence of adverse events during hospitalization.